We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+54.95%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$322M
Cap. Flow
+$104M
Cap. Flow %
9.75%
Top 10 Hldgs %
58.42%
Holding
77
New
21
Increased
11
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$67.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.7M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$22.6M
4
VTYX
Ventyx Biosciences
VTYX
+$16.9M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$14.1M

Top Sells

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$23.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$16.9M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$15.4M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.9B
$136M 12.66%
1,625,000
+375,000
+30% +$13.6M
SRPT icon
2
CALL
Sarepta Therapeutics
SRPT
$1.7B
$67.5M 6.3%
+700,000
New +$67.1M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.5B
$64M 5.98%
1,800,000
-450,000
-20% -$13.4M
APLS
4
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$59.9M 5.59%
1,000,000
+350,000
+54% +$17.8M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$56.9M 5.31%
950,000
+200,000
+27% +$10.1M
ARGX icon
6
argenx
ARGX
$56.7B
$55.2M 5.15%
+145,000
New +$67.6M
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1.07B
$54.4M 5.08%
4,383,875
+640,000
+17% +$8.6M
IMVT icon
8
Immunovant
IMVT
$8.27B
$50.6M 4.72%
1,200,000
-400,000
-25% -$14.7M
GPCR icon
9
Structure Therapeutics
GPCR
$3.53B
$43.6M 4.07%
1,070,058
+570,058
+114% +$32.7M
RCKT icon
10
Rocket Pharmaceuticals
RCKT
$357M
$38.2M 3.57%
1,275,000
-700,000
-35% -$15.4M
RYZB
11
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$35.3M 3.3%
+568,173
New +$14.1M
AMAM
12
DELISTED
Ambrx Biopharma Inc
AMAM
$29.9M 2.79%
2,100,000
+1,985,000
+1,726% +$22.6M
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.5M 2.66%
90,000
-25,000
-22% -$4.86M
IMCR icon
14
Immunocore
IMCR
$1.78B
$27.3M 2.55%
400,000
-50,000
-11% -$2.6M
DYN icon
15
Dyne Therapeutics
DYN
$4.2B
$25M 2.33%
1,880,000
-300,000
-14% -$2.93M
ANNX icon
16
Annexon
ANNX
$867M
$22.5M 2.1%
4,950,000
-350,000
-7% -$866K
INBX
17
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
$19M 1.77%
+500,000
New +$10.7M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$18.7M 1.74%
800,000
+200,000
+33% +$3.94M
OCUL icon
19
Ocular Therapeutix
OCUL
$1.91B
$17.8M 1.67%
+4,000,000
New +$11.8M
MOR
20
DELISTED
MorphoSys AG American Depositary Shares
MOR
$14.6M 1.36%
1,475,000
+525,000
+55% +$3.86M
DSGN icon
21
Design Therapeutics
DSGN
$748M
$13.3M 1.24%
5,032,501
– –
VRDN icon
22
Viridian Therapeutics
VRDN
$2.18B
$13.1M 1.22%
600,000
-450,000
-43% -$7.1M
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.45B
$10.4M 0.97%
+950,000
New +$6.67M
RVMD icon
24
Revolution Medicines
RVMD
$40B
$10M 0.94%
350,000
+100,000
+40% +$2.4M
MOR
25
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
$9.9M 0.92%
+1,000,000
New +$7.35M
1
2 3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2023 Portfolio in Review

As of Q4 2023, Logos Global Management held 77 positions worth $1.07B, up 43% from $750M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Logos Global Management deployed $104M of net new capital in Q4 2023, opening 21 new positions and adding to 11 existing holdings. Its largest new stake was argenx: 145,000 shares worth $55.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Icosavax, Inc. Common Stock, an estimated $23.7M trimmed.

  • Logos Global Management's largest Q4 2023 buy was argenx: 145,000 shares worth $55.2M.
  • Logos Global Management added most to Structure Therapeutics in Q4 2023, an estimated $32.7M increase.
  • Logos Global Management's biggest Q4 2023 reduction was Icosavax, Inc. Common Stock, cutting an estimated $23.7M.
  • Logos Global Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $19.2M.
  • Logos Global Management's ten largest holdings make up 58% of its $1.07B portfolio in Q4 2023.
  • Logos Global Management opened 21 new positions and closed 24 in Q4 2023.
  • Logos Global Management's portfolio value rose 43% quarter-over-quarter to $1.07B.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.